In October 2018, the first interim-analysis was performed, as half of our sample size was reached. There was no significant difference in functional outcome at three months between both groups, in an intention-to-treat analysis with adjustments for confounding variables. However, the DSMB advised to perform an additional interim-analysis when 75% (n=926/1235) of our sample size is included.
Investigators Meeting ESOC Barcelona
We will host the first TRUTH Investigators Meeting at the 2nd European Stroke Organisation Conference in Barcelona. The meeting will be held on the 10th of May at 12:45, in a boardroom at the conference center.
100 patients included!
In December 2015, the 100th patient was included in the TRUTH study.
The first patient was enrolled in the TRUTH study in the AMC in 2015.